Lebrikizumab
‘Don’t give up’: Long-term lebrikizumab for AD may benefit initial nonresponders
Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially responders to the treatment, according to a study.
Lebrikizumab effective in moderate to severe atopic dermatitis through 52 weeks
BOSTON — Patients with moderate to severe atopic dermatitis experienced relief with lebrikizumab for 52 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Eli Lilly’s first-quarter financial results highlight resubmission of BLA for lebrikizumab
Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.
Patients see fewer asthma exacerbations with lebrikizumab
Patients with asthma exacerbations and elevated blood eosinophils and fractional exhaled nitric oxide saw fewer exacerbations with lebrikizumab, according to a study published in the Journal of Allergy and Clinical Immunology: In Practice.
Lebrikizumab shows early efficacy in atopic dermatitis for patients with skin of color
SAN DIEGO — Atopic dermatitis improvement was found with lebrikizumab treatment in patients with skin of color, according to interim study results presented at the American Academy of Dermatology Annual Meeting.
Patients with atopic dermatitis maintain improvements for up to 2 years with lebrikizumab
WASHINGTON — Patients with moderate to severe atopic dermatitis treated with lebrikizumab maintained improvements in patient-reported outcomes, according to a poster presented here.
VIDEO: Study probes lebrikizumab for atopic dermatitis patients with skin of color
In this video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-13 blocker lebrikizumab from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
Lebrikizumab maintenance dosing achieves dermatitis clearance up to 2 years
Maintenance dosing of lebrikizumab sustained skin clearance, relieved itch and reduced disease severity for up to 2 years in patients with moderate to severe atopic dermatitis, Eli Lilly and Company announced in a press release.
FDA issues complete response letter for lebrikizumab for eczema treatment
The FDA has issued a complete response letter for Eli Lilly and Company’s lebrikizumab biologics license application for moderate to severe atopic dermatitis treatment, according to a manufacturer-issued press release.
European Medicines Agency recommends Ebglyss for atopic dermatitis treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the marketing authorization of Ebglyss for atopic dermatitis in patients aged 12 years and older, according to an Almirall press release.